This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pill Economics - Research Report On Arena Pharmaceuticals, Inc. And Amgen, Inc.

NEW YORK, January 23, 2013 /PRNewswire/ --

The European Medicines Agency, the continent's equivalent of the US's Food and Drug Administration, is voicing out concerns about Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) [ Full Research Report] [1] weight loss pill, Belviq due to alleged side effects like tumors and psychiatric events. Consequently, stock fell as much as 11 percent to fall below $9 per share.

The company has to prove the European agency and the Committee for Medicinal Products for Human Use - who discovered the side effects - that the slight variations in those side effects are relative to placebo and means nothing compared to the benefit of the drug. With this, Arena is expecting a final decision on EU approval in the first half of 2013.

However, a report from Motley Fool is showing optimism on the company's part, believing that the price reduction after the early January 2013 surge could help bring it back above the $10 range. This is due to the stock price recently breaking out of the $8-$9.50 range it stayed for more than six months last year.

In addition, Arena has sparked the interest of hedge funds, with some recently buying stocks in bulk. Roughly 29 million shares have been acquired by hedge funds in the previous quarter, led by Wellington Capital. Their movements were instrumental in the previous price bump.

Meanwhile, another biopharmaceutical firm Amgen, Inc. (NASDAQ:AMGN) [ Free Research Report] [ 2 ] has seen its stock price and revenues increase to $83.29 and $4.32 billion, respectively, but has been downgraded to "neutral" from "outperform" by Zacks. The target price was also lowered to $86 from $100.

The investment research firm says they are concerned about Amgen's dependence on Prolia/Xgeva for long-term growth, which are some of the company's several key products expected to lose patent protection in the following years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,062.88 +5.24 0.25%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs